Stock On Watch: Aegerion Pharmaceuticals, Inc: Armistice Capital Opened Big New Position

Stock On Watch: Aegerion Pharmaceuticals, Inc: Armistice Capital Opened Big New Position

The New Armistice Capital Holding in Aegerion Pharmaceuticals, Inc

Armistice Capital filed with the SEC SC 13G form for Aegerion Pharmaceuticals, Inc. The form can be accessed here: 000091957416016725. As reported in Armistice Capital’s form, the filler as of late owns 5.6% or 1,664,000 shares of the Health Care–company.

Aegerion Pharmaceuticals, Inc stake is a new one for the for this institutional investor and it was filed because of activity on November 7, 2016. We feel this shows Armistice Capital’s positive view for the stock.

Business Profile

Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT).

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

The stock increased 1.10% or $0.02 on November 15, hitting $1.84. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) has declined 44.41% since April 14, 2016 and is downtrending. It has underperformed by 49.10% the S&P500.

Aegerion Pharmaceuticals, Inc. is a biopharmaceutical firm engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The company has a market cap of $54.07 million. It operates through pharmaceuticals segment. It currently has negative earnings. The Company’s products include lomitapide and metreleptin.

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Ratings Coverage

Out of 5 analysts covering Aegerion Pharmaceuticals (NASDAQ:AEGR), 3 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 60% are positive. $31 is the highest target while $7 is the lowest. The $19.20 average target is 943.48% above today’s ($1.84) stock price. Aegerion Pharmaceuticals has been the topic of 9 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The firm has “Underperform” rating given on Friday, February 12 by Bank of America. The firm has “Neutral” rating given on Wednesday, November 11 by Bank of America. Guggenheim upgraded Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) rating on Monday, December 21. Guggenheim has “Buy” rating and $13 price target. Jefferies upgraded the shares of AEGR in a report on Tuesday, July 28 to “Buy” rating. The stock of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) earned “Hold” rating by Zacks on Friday, August 7.

More news for Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) were recently published by: Bostonglobe.com, which released: “Aegerion Pharmaceuticals to merge with Canadian drug maker” on June 15, 2016. Fool.com‘s article titled: “Why Aegerion Pharmaceuticals Is Crashing Today” and published on November 10, 2015 is yet another important article.

According to Zacks Investment Research, “Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutics to treat lipid disorders. Its products include Lomitapide and Implitapide. Lomitapide is a small molecule microsomal triglyceride transfer protein inhibitor, or MTP-I, that is used as an oral once-a-day treatment for patients with severe lipid disorders. Implitapide is used in the treatment of hypertriglyceridemia. Aegerion Pharmaceuticals, Inc. is headquartered in Bridgewater, New Jersey.”

AEGR Company Profile

Aegerion Pharmaceuticals, Inc., incorporated on February 4, 2005, is a biopharmaceutical company. The Firm is engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Firm operates through pharmaceuticals segment. The Company’s products include lomitapide and metreleptin.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment